<!DOCTYPE html>
<html lang="ko">
<head>
<meta charset="utf-8">
<meta http-equiv="x-ua-compatible" content="ie=edge">
<meta name="format-detection" content="telephone=no">
<meta name="viewport" content="width=device-width,initial-scale=1.0,shrink-to-fit=no">
<title>Document</title>
<meta property="og:url" content="">
<meta property="og:title" content="">
<meta property="og:type" content="website">
<meta property="og:image" content="">
<meta property="og:description" content="">
<link rel="stylesheet" type="text/css" href="../css/bootstrap.min.css">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/Swiper/4.5.1/css/swiper.min.css">
<link rel="stylesheet" type="text/css" href="../css/aos.css">
<link rel="stylesheet" type="text/css" href="../css/import.css">
<script src="../js/jquery-3.3.1.min.js"></script>
<script src="../js/bootstrap.bundle.min.js"></script>
<script src="../js/aos.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/Swiper/4.5.1/js/swiper.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/countup.js/1.7.1/countUp.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/waypoints/4.0.1/noframework.waypoints.min.js"></script>
</head>
<body>
<nav>
	<a href="#ct" class="skip sr-only sr-only-focusable">Go to content</a>
</nav>
<div id="wrap">
	<!-- Header -->
	<header id="hd" class="hd-eng">
		<div class="container">
			<div class="hd-inner">
				<h1 class="hd-logo text-hide"><a href="#">안국약품(주)</a></h1>
				<nav id="menu">
					<ul id="gnb" class="gnb">
						<li>
							<a href="#" class="btn-depth">Company</a>
							<ul class="depth dep1"> 
								<li><a href="#">Greetings</a></li>
								<li><a href="#">History</a></li>
								<li><a href="#">VISION</a></li>
								<li>
									<a href="#" class="btn-depth">IR</a>
									<ul class="depth dep2">
										<li><a href="#">Financial Information</a></li>
									</ul>
								</li>
							</ul>
						</li>
						<li>
							<a href="#" class="btn-depth">Product</a>
							<ul class="depth dep1">
								<li><a href="#">Product Search</a></li>
							</ul>
						</li>
						
						<li>
							<a href="#" class="btn-depth">PR Center</a>
							<ul class="depth dep1">
								<li><a href="#">Product Pipeline</a></li>
							</ul>
						</li>
						<li>
							<a href="#" class="btn-depth">R&amp;D</a>
							<ul class="depth dep1">
								<li><a href="#">R&amp;D VISION</a></li>
								<li><a href="#">History and Research Performance</a></li>
								<li><a href="#">Research &amp; Development Item</a></li>
								<li><a href="#">PRODUCT PIPELINE</a></li>
							</ul>
						</li>
					</ul>	
				</nav> 
				<!-- 사이트맵 -->
				<div id="siteMap">
					<div class="container">
						<ul class="sitemap">
							<li>
								<a href="#">Company</a>
								<ul>
									<li class="on"><a href="#">Greetings</a></li>
									<li><a href="#">History</a></li>
									<li><a href="#">VISION</a></li>
									<li><a href="#">IR</a>
										<ul>
											<li><a href="#">Financial Information</a></li>
										</ul>
									</li>
								</ul>
							</li>
							<li>
								<a>Product</a>
								<ul>
									<li><a href="#">Product Search</a></li>
								</ul>
							</li>
							
							<li>
								<a>PR Center</a>
								<ul>
									<li><a href="#">Ahn-gook Promotional Center</a></li>
								</ul>
							</li>
							<li>
								<a>R&amp;D</a>
								<ul>
									<li><a href="#">R&amp;D VISION</a></li>
									<li><a href="#">History and Research Performance</a></li>
									<li><a href="#">Research &amp; Development Item</a></li>
									<li><a href="#">PRODUCT PIPELINE</a></li>
								</ul>
							</li>
						</ul>
					</div>
				</div>	
				<div class="hd-util">
					<div class="hd-util-lang">
						<button type="button" class="dropdown-btn-lang" data-toggle="dropdown" aria-expanded="true">EN</button>
						<ul class="dropdown-menu">
							<li><a href="#">KR</a></li>
							<li class="active"><a href="#">EN</a></li>
						</ul>
					</div>
					<button type="button" class="gnb-btn">
						<span>Open / Close menu</span>
					</button>
				</div>
				<div class="gnb-dim"></div>
			</div>
		</div>
	</header>
	<!-- //Header -->

	<div class="dim"></div>
	<!-- Container -->
	<div id="ct">
<!-- 페이지 시작 -->
<div class="sub-content sub-rnd page-en">
	<div class="sub-hd">
		<div class="sub-hd-bg"></div>
		<div class="sub-hd-txt">
			<div class="sub-hd-txt-inner">
				<h2 class="sub-hd-tit">R&amp;D Product</h2>
				<p class="sub-hd-desc">Bringing health to life with the technology of Ahn-Guk Pharm. <br>We deliver hope for the future.</p>
			</div>
		</div>
	</div>
	<div class="sub-breadcrumbs no-tabs">
		<div class="wrap">	
			<div class="sub-breadcrumbs-inner">
				<div class="container">
					<ul class="sub-location">
						<li class="sub-location-home"><a href="#">Home</a></li>
						<li><a href="#">Company</a></li>
						<li><a href="#">R&amp;D</a></li>
						<li><a href="#" aria-current="page">R&D Product</a></li>
					</ul>
				</div>
			</div>
		</div>
	</div>
	<div class="sub-body">
		<div class="container-lg">
			<h3 class="display-1 text-center">R&D Product<b class="red-dot">.</b></h3>
			<ul class="nav nav-pills nav-justified">
				<li class="nav-item">
					<a href="#tab1" class="nav-link active" data-toggle="tab">Self-developed Drugs</a>
				</li>
				<li class="nav-item">
					<a href="#tab2" class="nav-link" data-toggle="tab">Technical Partnership Items</a>
				</li>
			</ul>
			<div class="tab-content">
				<div id="tab1" class="tab-pane active">
					<div class="cnt-wrp">
						<div class="cnt-inner border-0">
							<span class="cate right">R&amp;D PRODUCT</span>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-01.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Levosartan Tab.</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. The Korea’s first combination drug of S-Amlodipine besylate and Valsartan. <br>2. Shows a good blood pressure drop effect and reduces side effects caused by complementation of two ingredients. <br>3. Shows excellent physiochemical stability - No need of separate aluminum packaging, as it does not have properties of absorption.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>Blood Pressure</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-02.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Retopra Tab. (Korea’s first S-Pantoprazole-only formulation)</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. Developed as an S-Pantoprazole formulation with proven bioequivalence with Pantoprazole. <br>2. Shows efficacy equivalent to Pantoprazole at just a half dose.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>Peptic ulcer</dd>
										</dl>
									</div>
								</div>
							</div>
							
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-04.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Levomos Tab.</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. It helps to reduce eye dryness and fatigue and increase immunity. <br>2. Active vitamin B1 and benfotiamine quickly relieve the symptom of fatigue. <br>3. Antioxidative ingredients such as vitamin C, vitamin E, selenium, and zinc suppress cell damage from oxygen free radicals, a major aging cause.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>Blood Pressure</dd>
										</dl>
									</div>
								</div>
							</div>
							<!-- 220222 추가 -->
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-05.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Levotension Tab. (Korea’s first S-Amlodipine only formulation)</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. The existing RS-Amlodipine is a combination of S-Amlodipine and R-Amlodipine at a ratio of 50:50.<br> 2. S-Amlodipine is an active ingredient that lowers blood pressure and is 1000 times stronger in calcium channel blocking than R-Amlodipine.<br> 3.Levotension selectively blocks calcium channels using S-Amlodipine, an active ingredient.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>1. Blood pressure<br> 2. Fixed occlusion of the coronary artery<br> 3. Myocardial ischemia caused by spasm and contraction of coronary vascular system</dd>
										</dl>
										<dl>
											<dt>Related Papers</dt>
											<dd>1. J, Pharm Pharmaceut Sci, 2001;185-200.<br> 2. JMA-India, 2004;3(11)71-14. <br>3. Chirality, 1993;5(1):15-19.<br> 4. J, Cardiovasc, Pharmacol, 19995-25;25(2):268-272.<br> 5. JAMA-india, 2004;3(1)71-75.<br> 6. Chirality, 1989;1(3):209-215.<br> 7. J, Clin, Bas, Cardiol, 1998;1:14-18.<br> 8. Br, J, Pharmacol, 1988;95:55-66.</dd>
										</dl>
										<dl>
											<dt>Awarding Record</dt>
											<dd>1. Grand prize in the category of technology innovation in the 8th Korea Commodity Awards (May 31, 2008)</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-06.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Levotenol Tab. (Korea’s first S-Atenolol-only formulation)</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. Developed as an S-Atenolol formulation with biological equivalence with Atenodol.<br> 2. Demonstrates a blood pressure lowering effect equivalent to or greater than Atenolol in a comparative clinical trial in patients with hypertension.<br> 3. Levotenol showed a blood pressure lowering effect equivalent to or greater than Atenolol just at a half dose.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>1. Blood pressure<br> 2. Angina</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-07.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Anycough</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. A new concept of antitussive drug containing cocoa or chocolate extracts Has non-inferior antitussive effect to codeine</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>1. Relief of postnasal drip caused by rhinitis, rhinopharyngitis and sinusitis or cough caused by chronic bronchitis</dd>
										</dl>
										<dl>
											<dt>Related Papers</dt>
											<dd>1. The antitussive effect of theobromine, caffeine and reference codeine, on 15% citric acid spray Induced cough model in guinea pig after oral administration (1997)<br> 2. The time dependency of the antitussive effect of theobromine on 15% citric acid spray induced cough Model in guinea pig after oral administration (1997)<br> 3. Testing the antitussive effect of theonromine during chronic treatment on 15% citric acid spray evoked cough model in guinea-pig (1997)<br> 4. The effect of theobromine on the mucociliary clearance activity in rabbits airways(1997)</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-09.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Sedatol SR Tab. (New paradigm for the treatment of overactive bladder)</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. A next generation Tolterodine formulation that improves inconvenience of capsule and reduces the size and dose frequency.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>1. Treatment of overactive bladder with symptoms such as uncontrolled urge to pee, or urge to pee more frequently, or urge urinary incontinence</dd>
										</dl>
										<dl>
											<dt>Related Patents</dt>
											<dd>1. Drug composition patent application (10-2006-007059)</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-10.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Anyfen (100% active anti-inflammatory analgesic)</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. A 100% bio active anti-inflammatory drug, which is differentiated from Ibuprofen.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>1. Acute and chronic arthritis: Chronic polyarthritis, rheumatoid arthritis, etc<br> 2. Arthrosis <br>3. Inflammatory rheumatic disease: Ankylosing spondylitis, muscular rheumatism 4. Treatment aid of infectious disease accompanied by inflammation, pain and fever</dd>
										</dl>
										<dl>
											<dt>Related Patents</dt>
											<dd>1.J Clin Pharmacol 36;7S-15S, 1996 J Clin Pharmacol 36;88-94S, 1996<br> 2. J Clin Pharmacol 36;3S-6S, 1996</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-11.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Synatura syrup</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. An antitussive/expectorant drug with maximized active synergy from the combination of Western ivy leaf and Oriental goldthread. Ahn-gook’s nature-derived new drug No. 5 with safety and significant antitussive, expectorant, and anti-inflammatory effects.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>1. Acute upper respiratory infections, chronic inflammatory bronchitis</dd>
										</dl>
										<dl>
											<dt>Awarding Record</dt>
											<dd>1. A global leading nature-derived new drug selected by the Ministry of Knowledge Economy in 2011</dd>
										</dl>
									</div>
								</div>
							</div>
						</div>
						<div class="cnt-ft">
							<div class="btn-area">
								<a href="#" class="btn">더보기</a>
							</div>
						</div>
					</div>
				</div>
				<div id="tab2" class="tab-pane">
					<div class="cnt-wrp">
						<div class="cnt-inner border-0">
							<span class="cate right">R&amp;D PRODUCT</span>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-12.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<!-- 220222 수정 -->
									<h2 class="sub-grid-tit">Rupafin Tab. (Antihistamine new drug)</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. Dual action of antihistamine effect and inhibition of Platelet Activating Factor (PAF)<br> 2. Fast drug effect, extensive and powerful suppression of allergic reactions, and anti-inflammable effect<br> 3. The first antihistamine with proven long-term stability</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>Treatment of allergic rhinitis and allergic urticaria</dd>
										</dl>
										<dl>
											<dt>Related Papers</dt>
											<dd>1. Mullol J, et al, Allergy, 2015.<br> 2. Barron et al, Methods Find, Clin, Pharmacol, 2005;27(Suppl.2):161.<br> 3. Rarris et al, Allergy, 2000;55(63):94-95. <br>4. Stuebner P, et al, Ann Allergy Asthma lmmunol, 2006 Jan;96(1):37-44.<br> 5. Maiti R, et al, Arch Otolaryngol Head Neck Sung, 2010 Aug;136(8):796-800.<br> 6. Maiti R, et al, J Durgs Dematol, 2011 Dec;10(12):1444-50.<br> 7. Valero A, et al, Drugs Saf, 2009:32(1):33-42.</dd>
										</dl>
										<dl>
											<dt>Partner</dt>
											<dd>Uriach (Spain): Marketed in 70 countries since the launch in 2003</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-13.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Binosto Effervescent Tab.</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>1. An effervescent tablet for the treatment of osteoporosis, administered with water.<br> 2. Is more convenient to administer and less irritating to the gastrointestinal tract than the tablet formation.</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>Treatment of female osteoporosis after menopause, male osteoporosis</dd>
										</dl>
										<dl>
											<dt>Partner</dt>
											<dd>EffRx (Switzerland): U.S. FDA. Approved by the EMA</dd>
										</dl>
									</div>
								</div>
							</div>
							<div class="sub-cnts-type-grid">
								<div class="sub-grid-img prod-img">
									<img src="../img/rnd/prod-img-14.jpg" alt="">
								</div>
								<div class="sub-grid-cnt">
									<h2 class="sub-grid-tit">Forlax</h2>
									<div class="sub-grid-desc">
										<dl>
											<dt>Overview</dt>
											<dd>A new concept treatment of adult constipation symptoms</dd>
										</dl>
										<dl>
											<dt>Indication</dt>
											<dd>Treatment of adult constipation symptoms</dd>
										</dl>
										<dl>
											<dt>Partner</dt>
											<dd>Beaufor lpsen (France): Had the largest market share in French constipation drug market (2003)</dd>
										</dl>
									</div>
								</div>
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>


<!-- //페이지 끝-->
	</div>
	<!-- //Container -->

	<!-- Footer -->
	
	<!-- //Footer -->
</div>
<!-- //wrap -->
<script src="../js/common.js"></script>
</body>
</html>
